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Previous studies have demonstrated that the n-3 fatty acid EPA improves insulin resistance induced by high-fat diets. The aim of the present study
was to investigate the potential role of visfatin and apelin in the insulin-sensitising effects of EPA ethyl ester. The effects of EPA on muscle and
adipose GLUT mRNA, as well as on liver glucokinase (GK) and glucose-6-phosphatase (G6Pase) activity, were investigated. Male Wistar rats fed
on a standard diet or a high-fat cafeteria diet were daily treated by oral administration with EPA ethyl ester (1 g/kg) for 5 weeks. A significant
decrease (P,0·01) in white adipose tissue (WAT) visfatin mRNA levels was found in the cafeteria-fed rats, which was reversed by EPA admin-
istration (P,0·05). Moreover, a negative relationship was observed between homeostatic model assessment (HOMA) and the visfatin:total WAT
ratio. In contrast, cafeteria-diet feeding caused a significant increase (P,0·01) in apelin mRNA in visceral WAT. EPA increased (P,0·01) apelin
gene expression, and a negative relationship between HOMA index with visceral apelin mRNA and serum apelin:total WAT ratio was also
observed. EPA treatment did not induce changes in skeletal muscle GLUT1, GLUT4 or insulin receptor mRNA levels. Neither liver GK and
G6Pase activity nor the GK:G6Pase ratio was modified by EPA. These data suggest that somehow the insulin-sensitising effects of EPA could
be related to its stimulatory action on both visfatin and apelin gene expression in visceral fat, while changes in skeletal muscle GLUT, as well
as in hepatic glucose production, are not likely to be the main contributing factors in the improvement in insulin resistance induced by EPA.
Insulin resistance: Adipose tissue: Liver: Skeletal muscle
Obesity is considered to be one of the major risk factors
related to insulin resistance onset(1). However, not all types
of dietary fats appear to be as obesogenic and to produce
insulin resistance. In fact, there is much evidence suggesting
that the intake of n-3 fatty acids, especially EPA, produces
some improvements in insulin resistance and obesity features
in several models of obesity and diabetes in rodents(2 – 5).
However, the ultimate mechanisms sustaining the protective
effects of n-3 fatty acids are still unclear.
In this context, it is well known that adipose tissue is able to
synthesise and secrete adipokines that can modulate insulin
sensitivity both locally and in other organs(6). In fact, it has
been hypothesised that the regulation of these adipokines by
n-3 fatty acids could mediate their beneficial effects on insulin
resistance. For example, it was recently reported that EPA
administration increases the ability of adipocytes to produce
adiponectin, which could contribute to the insulin-sensitising
properties of this fatty acid(4,7,8).
The recent identification of two new adipokines, visfatin and
apelin, with an important potential role in insulin resistance, has
led to investigation of the effects of n-3 fatty acids on their
regulation. Visfatin was recently identified as a secreted protein
expressed and regulated in adipose tissue with a predominant
abundance in visceral fat depots(9). An insulin-like action of
this adipokine was initially reported both in vivo and in vitro
due to a specific binding of visfatin with the insulin receptor(9).
However, other studies found that visfatin does not exert any
insulin-mimetic effects(10). It has been reported that expression
and circulating levels of visfatin increase in obesity and
diabetes(9,11,12); however, there are some controversial results
concerning these features(13,14).
Regarding apelin, it has been shown that this adipokine is
up-regulated in rodents and man during obesity, and that a
strong relationship exists between adipocyte-secreted apelin
and insulin levels(15 – 17). In fact, plasma apelin concentrations
have been associated with hyperinsulinaemia, and the insulin-
deficient mice (streptotocin-treated) showed lower mRNA
levels of apelin as compared with controls(15). It has been
hypothesised that over-production of apelin in the obese
could be one of the last protective defences before the emer-
gence of obesity-related disorders such as insulin resistance
and type 2 diabetes(18).
In addition to their effects on adipokines, it has been
suggested that n-3 fatty acids could also exert their positive
actions on insulin sensitivity by modifying the levels of GLUT
(GLUT1 and GLUT 4) in muscle and adipose tissue(3,19).
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Furthermore, n-3 fatty acids could also improve hypergly-
caemia and hyperinsulinaemia by regulating the hepatic
enzymes involved in glucose phosphorylation (glucokinase;
GK) or dephosphorylation (glucose-6-phosphatase; G6Pase),
which control glucose utilisation and production by this
organ(20,21).
In the present study, we investigated the effects of the n-3
fatty acid EPA on visfatin and apelin circulating concen-
trations and mRNA expression levels in lean and overweight
rats, as well as the effect of EPA on muscle and adipose
GLUT mRNA and liver GK and G6Pase activity. We demon-
strate for the first time that EPA stimulates visfatin and apelin
adipose tissue production, which could be involved in its prop-
erties to protect against the development of insulin resistance.
Experimental methods
Animals and treatment
Twenty-nine male Wistar rats (aged 6 weeks), obtained from
the Centre of Applied Pharmacology (CIFA, Pamplona,
Spain), were housed (two or three per cage) in a temperature-
controlled room (22 ^ 28C) with a 12 h light–dark cycle.
All experimental procedures were performed under protocols
approved by the University Ethics Committee for the use of
laboratory animals, according to the National and Institutional
Guidelines for Animal Care and Use. Animals were distributed
in four experimental groups: control, control-EPA, overweight
and overweight-EPA groups. All animals were maintained in
an adaptation period of 4 d on a chow diet (Rodent Toxicology
Diet; B&K Universal, Hull, UK) and given deionised water
ad libitum. After this period of time, control and control-EPA
groups were fed a standard pelleted diet (Rodent Toxicology
Diet; B&K Universal) containing 76 % of carbohydrates, 6 %
of lipids and 18 % of proteins (1515 kJ/100 g (362 kcal/
100 g)). On the other hand, the overweight and overweight-
EPA groups were fed a cafeteria diet composed of the follow-
ing items: paˆte´, chips, bacon, chocolate, biscuits and pelleted
diet (2:1:1:1:1:1, by wt.)(22). The composition of this diet was
9 % energy as protein, 29 % as carbohydrate and 62 % as
lipid by dry weight. All the animals had ad libitum access to
water and food during 5 weeks. Simultaneously, the control-
EPA and overweight-EPA groups were daily treated by oral
administration with highly purified EPA ethyl ester (1 g/kg
animal weight) during 35 d, whereas the same volume of
water was orally administrated to the control and overweight
groups, as previously shown in other studies(3,23,24). These con-
trol and overweight groups without treatment with any other
type of fatty acid (such as SFA with equal chain length as
EPA or oleic acid) could be adequately considered as control
groups in our study design, as previously published(4), since it
has been demonstrated that supplementation with some other
fatty acids is able to modify adiposity and the circulating
levels of biochemical and hormonal markers planned to be
determined in the present study(3).
Body weight and food intake were measured daily. At
the end of the experimental period, and after an overnight
fast, animal were euthanised by decapitation. The collected
gastrocnemius muscle, liver and visceral white adipose
tissue (WAT) depots were frozen in liquid N2 and stored
at 2808C(4).
RNA analysis and quantitative real-time polymerase chain
reaction
Total RNA was extracted from liver, visceral adipose tissue
and muscle, according to the Gibco Life Technologies pro-
cedure using Trizol (Life Technologies Inc., Grand Island,
NY, USA). UV absorbance and integrity gels were used to
estimate RNA. After this process, 5mg RNA were treated
with DNA-freee (Ambion Inc., Streetsville, ON, Canada)
in a total reaction volume of 24ml during 30 min at 378C.
Of this product, 13ml were retrotranscripted to cDNA. Reac-
tion conditions of retrotranscription were as follows: 60 min at
378C and 5 min at 958C. For real-time PCR amplification, 9ml
cDNA per reaction were used.
TaqMan probes for rat apelin (Rn00581093_m1), visfatin/
PBEF1 (Rn00822046_m1), GLUT1 (Rn00593670_m1), GLUT4
(Rn00562597_m1), insulin receptor (Rn00567070_m1) and 18S
(Hs99999901_s1) were Assay-on-Demand gene expression
products. All of the reagents for real-time PCR analysis of
genes (TaqMan RT reagents and TaqMan Universal PCR
Master mix) were purchased from Applied Biosystems (Foster
City, CA, USA) and the conditions were used according to
the manufacturer’s protocol. Amplification and detection
of specific products were performed with the ABI PRISM
7000HT Sequence Detection System (Applied Biosystems).
18S RNA was used as the reference to normalise the
expression levels between samples, allowing data to be
expressed relative to 18S RNA, therefore compensating
for any differences in RT efficacy. All standards and samples
were analysed in duplicate. Data were obtained as cycle
threshold (Ct) values (the cycle at where the fluorescence
signal emitted is significantly above background levels and is
inversely proportional to the initial template copy number)
according to the manufacturer’s guidelines, and used to deter-
mine DCt values (DCt ¼ Ct of the target gene 2 Ct of the
housekeeping gene) of each sample. Fold changes of gene
expression were calculated by the 22DDCt method(25).
Enzymic determinations
Liver GK activity was measured by spectrophotometrical
detection of the NADH produced by the glucose-6-phosphate
dehydrogenase (G6PDH)-induced dehydrogenation of glu-
cose-6-phosphate in the presence of ATP and NADþ(26).
The tissue (0·6 g in 10 ml of 50 mM 2-amino-2-hydroxy-
methyl-propane-1,3-diol (Tris)–HCl buffer, pH 7·4) was
homogenised and subsequently centrifuged at 12 000 g for
60 min at 48C, and then the supernatant fractions were
collected. Then 10ml of the supernatant fractions were incu-
bated with 5·5ml G6PDH and 985ml of enzymic substrate
(100 mM-glucose, 5 mM-ATP, 1 mM-NAD and 7·5 mM-MgCl2
in 100 mM-Tris–HCl buffer, pH 7·4) during 10 min in a
temperature-controlled bath at 378C. Samples were incubated
at 48C to stop the reaction, and then the absorbances were
measured in a spectrophotometer at 340 nm(27).
Furthermore, liver G6Pase activity was quantified by
measuring the phosphate released from the dephosphorylation
of glucose-6-phosphate by G6Pase. Briefly, 0·5 g liver
were homogenised in 4·5 ml 0·25 M-sucrose-HEPES buffer
(pH 7·4) and subsequently centrifuged at 30 000 g for 10 min
at 48C. Then the supernatant fraction was centrifuged at
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100 000 g for 60 min at 48C. The pellet obtained was re-sus-
pended again in the same buffer and the centrifugation was
repeated for washing the pellet. This pellet, which contained
the microsomes, was then re-suspended in 0·9 ml of the
same buffer. A mixture of 100ml of microsomes and 400ml
of reactive solution (1 mM-glucose-6-phosphate, 0·25 mM-
CaCl2 and 1·25 mM-EDTA in 100 mM-Tris–HCl buffer, pH
7·3) was incubated at 378C during 6 min in a temperature-con-
trolled shaking bath. To stop the reaction, 2 ml ascorbic acid–
TCA solution (2–10 %, w/v) were then added. The released
phosphate was measured using the method of Fiske–Sub-
barow(28) and expressed relative to the protein content in the
homogenate(29).
Serum visfatin and apelin determinations
Serum visfatin and apelin levels were measured by ELISA kits
from ALPCO Diagnostics Ltd (Salem, NH, USA) and Phoenix
Pharmaceuticals Inc. (Belmont, CA, USA) respectively,
according to the manufacturers’ guidelines.
Statistical analysis
Statistical differences and interactions were evaluated through
a factorial two-way ANOVA (diet £ EPA treatment). When
statistically significant differences resulted at the interaction
level, a Student’s t test was carried out to compare
the effects of each treatment (GraphPad Prism; GraphPad
Software Inc., San Diego, CA, USA). Furthermore, Pearson
correlation analysis was performed to screen potential associ-
ation between two variables. Differences were considered as
statistically significant at P,0·05.
Results
Effects of eicosapentaenoic acid ethyl ester on body and fat
pad weights and on glucose and insulin serum levels
The administration of EPA ethyl ester (1 g/kg) was able to par-
tially prevent the body-weight gain induced by the cafeteria
diet in rats (Table 1), although it did not reach statistical
significance. Furthermore, EPA treatment tended to decrease
the weight of all the fat pads, especially in the group of
animals fed with a standard diet. In this sense, a significant
reduction (P,0·05) in retroperitonal adipose tissue weight
was observed in EPA-treated rats. Although no significant
changes were observed in serum glucose levels, EPA treat-
ment induced a significant reduction (P,0·05) in insulin
plasma levels (Table 1). Moreover, insulin sensitivity was ana-
lysed by assessing the insulin:glucose ratio and the homeo-
static model assessment (HOMA) index. The HOMA index
was initially defined as an index of insulin resistance in
humans(30). Even though HOMA index has not been validated
for animal studies(31), several trials have demonstrated that the
HOMA index can be useful to compare the resistance to insu-
lin between groups in rodents(4,32 – 35). Our data revealed that
both the insulin:glucose ratio and HOMA index were signifi-
cantly decreased (P,0·05) in EPA ethyl ester-treated rats,
suggesting the ability of EPA supplementation to increase
insulin sensitivity (Table 1).
Effects of eicosapentaenoic acid ethyl ester on visfatin
circulating and gene expression levels
A significant decrease (P,0·01) in visfatin mRNA levels
in visceral WAT was found in cafeteria-fed rats, which
was reversed by EPA ethyl ester administration (P,0·05)
(Fig. 1 (a)). However, no significant changes were found in
visfatin circulating levels (Fig. 1 (b)), despite the different
size of fat depots exhibited by cafeteria-fed rats in comparison
with EPA-treated animals. Adipose secretion of several
adipokines, such as leptin and adiponectin, has been shown
to be dependent on adipose mass size(36). In order to estimate
the capacity of adipose tissue to produce visfatin and the
involvement of visfatin from fat pads in the total blood
concentration, serum levels of this adipokine were corrected
for adiposity (visfatin per g total WAT). Then, a significant
decrease in the vistatin:total WAT ratio (P,0·05) was
obtained in the cafeteria-fed groups (Fig. 1 (c)). In addition,
our present data showed an inverse relationship between
serum visfatin levels corrected for adiposity and HOMA
index (r 20·436; P,0·05).
Table 1. Effects of EPA ethyl ester (35 d of treatment) on body and fat weights, and on circulating levels of glucose, insulin and index of insulin resist-
ance in lean and overweight rats*
(Mean values with their standard errors)
Control (n 8)
Control-EPA
(n 7)
Overweight
(n 7)
Overweight-
EPA (n 7) 2 £ 2 ANOVA
Mean SE Mean SE Mean SE Mean SE Diet EPA Diet £ EPA
Initial body weight (g) 181·1 2·4 181·2 2·3 186·2 2·4 179·1 6·6 NS NS NS
Final body weight (g) 310·6 8·1 307·8 4·4 361·5 6·4 330·7 11·8 P,0·001 NS NS
Body weight gain (g) 129·2 7·3 126·6 4·8 175·4 6·8 151·6 1·1 P,0·001 NS NS
Retroperitoneal fat (g) 6·7 0·72 3·8 0·4 11·2 1·2 9·7 0·9 P,0·001 P,0·05 NS
Glucose (mM) 5·3 0·2 5·2 0·2 5·8 0·2 5·3 0·2 P¼0·08 NS NS
Insulin (mUnits/ml) 23·3 3·9 11·2 0·8 28·2 6·7 19·9 2·4 NS P,0·05 NS
Insulin:glucose ratio 4·4 0·7 2·2 0·2 5·0 1·2 3·7 0·5 NS P,0·05 NS
HOMA† 5·4 0·9 2·5 0·1 7·1 1·6 4·8 0·5 NS P,0·05 NS
HOMA, homeostatic model assessment.
* Data were analysed by a two-way factorial ANOVA.
† HOMA ¼ insulin (mUnits) £ glucose (mmol/l)/22·5.
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Effects of eicosapentaenoic acid ethyl ester on apelin
circulating and gene expression levels
In contrast to findings concerning visfatin, cafeteria-diet feed-
ing caused a significant increase (P,0·01) in apelin mRNA
expression in visceral WAT. Similarly, the administration of
EPA ethyl ester also induced a significant increase (P,0·01)
in apelin gene expression (Fig. 2 (a)). A similar pattern of
increased apelin circulating levels in cafeteria-fed rats was
observed, although no statistically significant differences
were detected (Fig. 2 (b)). Furthermore, our data also
showed that both apelin mRNA and the serum apelin:total
WAT ratio were negatively correlated (P,0·05) to the
HOMA index (Fig. 2 (c) and (d)).
Effects of eicosapentaenoic acid ethyl ester on mRNA levels of
glucose transporters (GLUT-1 and GLUT-4) and insulin
receptor
As shown in Table 2, no significant effects either by the
cafeteria-diet feeding or by EPA administration were observed
on GLUT1 and GLUT4 as well as on insulin receptor mRNA
levels in gastrocnemious skeletal muscle. However, a signifi-
cant decrease (P,0·05) in GLUT-1 and GLUT-4 gene
expression levels was found in visceral adipose tissue from
EPA ethyl ester-treated rats, while no changes were induced
in adipose tissue GLUT by the cafeteria-diet feeding (Table 2).
Effects of eicosapentaenoic acid ethyl ester on hepatic
glucokinase and glucose-6-phosphatase
A significant increase (P,0·05) in GK activity was observed
in cafeteria-fed rats, while no significant changes were found in
EPA-treated rats. G6Pase activity, as well as the GK:G6Pase
ratio, which reflects hepatic glucose production, was not modi-
fied either by the cafeteria diet or EPA treatment (Table 3).
Discussion
In agreement with previous studies using different models of
obesity and/or diabetes(3,4,22,23), our data demonstrate the abil-
ity of EPA ethyl ester (1 g/kg) to improve insulin sensitivity.
A primary goal of the present trial was to find out the potential
role of adipose visfatin and apelin, two recently described
adipokines, in the insulin-sensitising effects of EPA ethyl
ester. Visfatin, which appears to be preferentially produced
by visceral adipose tissue, is an adipokine with a controversial
capacity to bind and activate the insulin receptor both in vivo
and in vitro (9,10). It has also been suggested that visfatin
could be a missing link between intra-abdominal obesity and
diabetes(9,37). However, controversial results about the role
of visfatin in the regulation of glucose metabolism, insulin
resistance and obesity situations have been recently described.
Thus, although some studies have shown that serum and
visceral fat visfatin mRNA levels are increased in obesity
and type 2 diabetes(9,11), visfatin gene expression in visceral
adipose tissue of Wistar Ottawa Karlsburg W (WOKW) rats,
a model of polygenic metabolic syndrome, was similar to
that observed in lean control animals(38). Furthermore, some
recent trials have even described that visfatin is down-regu-
lated by overfeeding human subjects(13) and that circulating
levels of visfatin are negatively correlated with visceral fat
in humans genetically predisposed to develop insulin resist-
ance(39). Pagano et al. (14) observed that plasma visfatin
levels were reduced in human obesity. Our data suggest that
overfeeding with a diet rich in saturated fat impairs visfatin
gene transcription in visceral fat. The fact that cafeteria-fed
rats exhibit similar serum levels of visfatin to the control
rats, despite their higher adiposity, suggests that the ability
Fig. 1. Effects of EPA ethyl ester on visfatin gene expression and circulating
levels in lean and overweight rats. (a) Visfatin mRNA expression levels in
visceral white adipose tissue (WAT) obtained by real-time PCR. Data were
calculated by the 22DDCt method, where Ct is cycle threshold. The mean
value for the control group was set at 1 and 18S RNA was used as the refer-
ence to normalise the expression levels. The effect of diet was significant
(P,0·01), the effect of EPA treatment was significant (P,0·05) and the
interaction between diet and EPA treatment was NS. (b) Visfatin circulating
levels. The effect of diet was NS, the effect of EPA treatment was NS and
the interaction between diet and EPA treatment was NS. (c) Visfatin concen-
trations expressed per g WAT. The effect of diet was significant (P,0·05),
the effect of EPA treatment was NS and the interaction between diet
and EPA treatment was NS. Data are means from at least seven indepen-
dent animals per group, with standard errors represented by vertical
bars. Data were analysed by two-way ANOVA. CEPA, control-EPA; OEPA,
overweight-EPA.
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of adipose tissue to produce visfatin is decreased in over-
weight animals. Indeed, the serum visfatin:total WAT ratio
was significantly decreased in these cafeteria-fed animals.
Longer periods of cafeteria feeding (more than 35 d) would
probably be necessary to observe lower circulating levels of
visfatin. A lack of concordance between visfatin circulating
levels and gene expression in different fat depots has also
been observed in other studies. Thus, Pagano et al. (14)
found that in human obesity plasma visfatin levels are
reduced, whereas visfatin mRNA was significantly higher in
visceral fat, together with a down-regulation of the visfatin
gene in subcutaneous fat. In contrast, Berndt et al. (40) found
that increased visfatin plasma concentrations in obesity corre-
late positively with visceral and negatively with subcuta-
neous visfatin mRNA levels. These facts suggest a complex
divergent regulation of this adipokine in different fat depots.
Fig. 2. Effects of EPA ethyl ester on apelin gene expression and circulating levels in lean and overweight rats. (a) Apelin mRNA expression levels in visceral white
adipose tissue (WAT) obtained by real-time PCR. Data were calculated by the 22DDCt method, where Ct is cycle threshold. The mean value for the control group
was set at 1 and 18S RNA was used as the reference to normalise the expression levels. Data are means from at least seven independent animals per group,
with standard errors represented by vertical bars. Data were analysed by two-way ANOVA. The effect of diet was significant (P,0·01), the effect of EPA treatment
was significant (P,0·01) and the interaction between diet and EPA treatment was NS. CEPA, control-EPA; OEPA, overweight-EPA. (b) Apelin circulating levels.
Data are means from at least seven independent animals per group, with standard errors represented by vertical bars. Data were analysed by two-way ANOVA.
The effect of diet was NS, the effect of EPA treatment was NS and the interaction between diet and EPA treatment was NS. (c) Correlation between mRNA apelin
expression levels and homeostatic model assessment (HOMA) index (r 20·3105; P¼0·0427). (A) Control; ( ), CEPA; (O), overweight; (K), OEPA. (d) Correlation
between serum apelin levels corrected for adiposity and HOMA index (r 20·4645; P¼0·019).
Table 2. Effects of EPA ethyl ester on mRNA expression levels of GLUT (GLUT-1 and GLUT-4) and insulin receptor (IR) in skeletal muscle (gastrocne-
mious) and visceral adipose tissue from lean and overweight rats*
(Mean values with their standard errors)
Control (n 8)
Control-EPA
(n 7)
Overweight
(n 7)
Overweight-
EPA (n 7) 2 £ 2 ANOVA
Mean SE Mean SE Mean SE Mean SE Diet EPA Diet £ EPA
Muscle GLUT-1 1·00 0·34 1·20 0·27 1·09 0·17 0·98 0·12 NS NS NS
Muscle GLUT-4 1·00 0·12 0·86 0·10 0·83 0·08 0·84 0·13 NS NS NS
Muscle IR 1·00 0·09 0·86 0·15 0·79 0·11 0·68 0·13 NS NS NS
Adipose tissue GLUT-1 1·00 0·39 0·50 0·06 1·07 0·24 0·6 0·11 NS P,0·05 NS
Adipose tissue GLUT-4 1·00 0·16 0·73 0·16 1·69 0·86 0·65 0·14 NS P,0·05 NS
Ct, cycle threshold.
* Data were calculated by the 22DDCt method. 18S RNA was used as the reference to normalise the expression levels. The mean value for the control group was set at 1. Data
were analysed by a two-way factorial ANOVA.
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Moreover, visfatin is also expressed in skeletal muscle, liver
and immune cells, whose function is also altered in obesity
and it is likely that these tissues may also contribute to
serum visfatin concentrations(14,41).
Our data also demonstrate the ability of EPA ethyl ester to
prevent the decrease of visfatin gene expression induced by
the cafeteria diet. In this context, it has been described that
visfatin increased after weight and adiposity loss induced
by gastroplastic surgery(42). This finding suggests that the
up-regulation of visfatin gene expression in visceral adipose
tissue could be due to the reducing effects of EPA treatment
on the size of this fat depot(4). However, a direct stimulatory
action of EPA on visfatin gene expression cannot be ruled
out, similarly to what we have observed with leptin(43).
The physiopathological role of visfatin in the development
of insulin resistance remains largely unknown(44). Some
studies have suggested that visfatin is not related to insulin
resistance in man(14). However, other studies have demon-
strated that circulating levels of visfatin are negatively
correlated with insulin resistance(39), and its plasma levels
are decreased in diabetics compared with non-diabetic
subjects(45). The present study shows a negative correlation
between the serum visfatin:total WAT ratio and HOMA
index, supporting the idea that the increase in visfatin
secretion could lead to an improvement in insulin resistance.
In fact, our data suggest that the up-regulation of visfatin
mRNA levels could contribute, at least in part, to the ben-
eficial actions of treatment with the n-3 fatty acid EPA on
insulin sensitivity. In this context, a recent study has shown
that fatty acids such as oleic and palmitic acids may induce
insulin resistance in 3T3-L1 adipocytes and preadipocytes,
and that the down-regulation induced by these fatty acids on
visfatin mRNA may contribute to impair insulin sensitivity(46).
In addition, and in agreement with our trial, it was also
described that the up-regulation of visfatin gene expression
could be a mechanism through which PPAR-a, PPAR-g and
PPAR-d agonists induced an improvement of insulin sensi-
tivity in genetic obese and insulin-resistant Otsuka Long-
Evans Tokushima Fatty (OLETF) rats(47) and in Wistar rats
fed on a high-fat diet(48). Moreover, it was described that
the increase in circulating concentrations of visfatin after
weight loss correlated with the decrease in plasma insulin con-
centration and HOMA of insulin resistance(42). It has also been
demonstrated that the release of the adipocytokine visfatin is
regulated by glucose and insulin both in vivo and in vitro (49).
In fact, hyperinsulinaemia inhibits visfatin gene expression
and secretion(50,51). These facts lead us to suggest that the
reduced levels of basal insulin observed after EPA treatment(4)
could also contribute to the up-regulation of visfatin gene
expression induced by EPA treatment.
Apelin was characterised as a novel adipose-expressed
factor that increases during adipocyte differentiation, being
also up-regulated in rodent and human obesity(15,45). Our
experimental data revealed a significant increase in visceral
apelin mRNA levels in cafeteria-fed rats. This is in agreement
with a recent study that found positive associations between
apelin gene expression levels in subcutaneous adipose tissue
and the excessive weight gain induced by cafeteria feeding(51).
In addition, it was recently reported that the increase of
some parameters involved in insulin resistance development,
such as fat mass, insulin, glucose and lipid plasma levels
and TNF-a gene expression, may positively influence apelin
circulating levels by regulating its expression(45,52). However,
EPA treatment, which has been shown to decrease basal
insulin concentrations, HOMA index and adipose TNF-a
mRNA(4) also induced a significant increase in apelin gene
expression. Although a similar trend was observed for serum
levels, no statistically significant changes were reached, prob-
ably because of the high variability of the data. Moreover,
if EPA treatment were to last more than 5 weeks or if a
higher dose were administered, it might be possible to observe
significant changes in apelin, as well as in visfatin, levels.
In this sense, it has previously been hypothesised that over-
production of apelin in the situation of obesity could be
one of the last protective defences before type 2 diabetes
develops(18). This idea suggests that the improvement in
insulin resistance observed in EPA ethyl ester-treated rats
could be associated, at least in part, to the increase in apelin
gene expression and secretion by adipose tissue. Indeed, our
data revealed a negative correlation between both apelin
mRNA levels and the serum apelin:total WAT ratio with the
HOMA index, supporting the relationship between insulin
sensitivity and the amount of apelin produced by adipose
tissue. In agreement with this idea, it was recently published
that the intraperitoneal administration of apelin increased insu-
lin sensitivity in vivo by influencing circulating adiponectin
levels, the expression of brown adipose tissue uncoupling
protein 1 and energy expenditure in mice(53).
On the other hand, it has been reported that the expression of
GLUT1 and GLUT4 in WAT, as well as GLUT4 in skeletal
muscle, is decreased by high-fat feeding and insulin resistance
conditions(54 – 56). In addition, it has been suggested that fish
oils could prevent insulin resistance by the prevention of the
decreased expression of GLUT4 in both skeletal muscle and adi-
pose tissue(21,56,57). However, in our experimental model of diet-
induced obesity, we only found a tendency to decrease GLUT4
Table 3. Effects of EPA ethyl ester on liver glucose-6-phosphatase (G6Pase) and glucokinase (GK) activity, and on G6Pase:GK ratio in lean and over-
weight rats*
(Mean values with their standard errors)
Control (n 8)
Control-EPA
(n 7)
Overweight
(n 7)
Overweight-
EPA (n 7) 2 £ 2 ANOVA
Mean SE Mean SE Mean SE Mean SE Diet EPA Diet £ EPA
G6Pase (mmol/g £ min) 4·66 1·69 4·78 1·43 4·38 0·71 3·98 0·69 NS NS NS
GK (mmol/g £ min) 10·98 1·37 9·20 0·47 15·60 2·63 14·14 3·05 P,0·05 NS NS
G6Pase:GK ratio 0·47 0·32 0·53 0·17 0·34 0·16 0·37 0·24 NS NS NS
* Data were analysed by a two-way factorial ANOVA.
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mRNA in skeletal muscle, although this was not statistically sig-
nificant, and no changes in adipose tissue GLUT1 or GLUT4
mRNA levels were observed in cafeteria-fed rats. Moreover,
in the present study the treatment with EPA-ethyl ester during
5 weeks did not induce any significant change in muscle
GLUT. This is agreement with the study of Taouis et al. (58),
which reported that Wistar rats maintained during 4 weeks
with a high-fat diet rich in n-3 PUFA showed changes in
muscle membrane phospholipids, without affecting muscle
GLUT-4 content. However, a previous study from Mori
et al. (3) showed that daily administration of EPA ethyl ester
during 17–18 weeks caused a significant increase in GLUT4
mRNA in skeletal muscle. Furthermore, and contrary to what
could be expected, the present study shows that EPA ethyl
ester treatment decreases adipose tissue GLUT1 and GLUT4
mRNA. This could be a mechanism by which EPA prevents glu-
cose entrance into adipocytes and, consequently, reduces the
synthesis of new fatty acids in WAT and adiposity, effects
mainly observed in the retroperitoneal fat pad(4). In this context,
Minami et al. (59) reported that the beneficial effect of EPA ethyl
ester on insulin sensitivity seems to be related to a decreased
abdominal fat accumulation. Thus, our data showed a significant
reduction in the retroperitoneal fat pad (225 %) mediated by
EPA administration, an effect that could also contribute to
improved insulin sensitivity. Taouis et al. (58) observed that
GLUT4 mRNA was diminished in rats fed a high-fat diet
enriched with n-6 fatty acids, while GLUT4 mRNA was
unaffected in those enriched with n-3. These apparently contro-
versial effects between different studies could be explained
by the different durations of the high-fat feeding and the
treatment with fish oils or only with highly purified EPA, the
composition of the diet, and/or the strain and physiological
conditions (normal, obese, diabetic) of rats used in these studies.
It has also been suggested that the protective effect of n-3
fatty acids on insulin resistance could be due to the suppres-
sion of both the activity and expression of G6Pase, leading
to a decrease in excessive hepatic glucose output(21,60). Liver
GK is a key enzyme involved in the regulation of glucose
storage in hepatocytes(61). However, our experiments did not
reveal any significant effect of EPA ethyl ester treatment
on GK and G6Pase activity, as well as on the G6Pase:GK
ratio (which roughly reflects hepatic glucose production),
suggesting that the possible diminution in glucose production
by the liver is not the major factor contributing to the improve-
ment in insulin resistance in EPA ethyl ester-treated rats.
In conclusion, our data demonstrate the ability of EPA ethyl
ester to prevent the decrease induced by the cafeteria diet in
visfatin and apelin mRNA levels in visceral adipose tissue,
and suggest that these effects could contribute, at least in
part, to the insulin-sensitising effects of EPA. Our data also
would indicate that changes in skeletal muscle GLUT, as
well as in hepatic glucose production, are not likely to be
major factors contributing to the improvement in insulin
resistance after EPA ethyl ester treatment.
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